Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-cash Items (2019 - 2024)

Historic Non-cash Items for Arcturus Therapeutics Holdings (ARCT) over the last 6 years, with Q4 2024 value amounting to $9.2 million.

  • Arcturus Therapeutics Holdings' Non-cash Items fell 8264.94% to $9.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.2 million, marking a year-over-year decrease of 8264.94%. This contributed to the annual value of $9.2 million for FY2024, which is 14987.22% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Non-cash Items stood at $9.2 million for Q4 2024, which was down 8264.94% from $53.3 million recorded in Q4 2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Non-cash Items ranged from a high of $53.3 million in Q4 2023 and a low of $718301.0 during Q4 2020
  • In the last 5 years, Arcturus Therapeutics Holdings' Non-cash Items had a median value of $10.7 million in 2022 and averaged $24.2 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 8693.52% in 2020, then skyrocketed by 645867.11% in 2021.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Non-cash Items stood at $718301.0 in 2020, then skyrocketed by 6458.67% to $47.1 million in 2021, then plummeted by 77.24% to $10.7 million in 2022, then skyrocketed by 397.11% to $53.3 million in 2023, then plummeted by 82.65% to $9.2 million in 2024.
  • Its Non-cash Items stands at $9.2 million for Q4 2024, versus $53.3 million for Q4 2023 and $10.7 million for Q4 2022.